Conference Correspondent

Combined Ibrutinib and Venetoclax in Patients with Treatment-Naïve High-Risk CLL

Conference Correspondent - ASH 2018 - CLL

Bruton’s tyrosine kinase and B-cell lymphoma-2 inhibition are thought to show complementary biological activity in treating chronic lymphocytic leukemia (CLL). At the ASH 2018 Annual Meeting, researchers reported results of an investigator-initiated phase 2 trial of combined ibrutinib (IBR) and venetoclax (VEN) as first-line treatment for patients with CLL.

To be eligible for study inclusion, all patients had at least 1 high-risk feature, which included del(17p), mutated TP53, del(11q), unmutated IGHV, or age ≥65 years. Patients received IBR monotherapy (420 mg daily) for 3 cycles followed by the addition of VEN escalated weekly to a target dose of 400 mg daily. The primary end point was complete remission (CR) or CR with incomplete bone marrow recovery (CRi).

A total of 80 patients were enrolled in the study. The median age was 65 years, with 30% of patients aged ≥70 years. Of the enrollees, 83% had unmutated IGHV, 18% had del(17p), 14% had TP53 mutation, and 25% had del(11q). The median follow-up for all patients was 14.8 months.

After 3 months of IBR monotherapy, the majority (57%) of evaluable patients showed a partial response. After the addition of VEN, increasing proportions of patients achieved CR/CRi and bone marrow undetectable minimal residual disease (BM U-MRD) remission. At 6 months of IBR-VEN treatment, 73% of patients achieved CR/CRi and 40% achieved BM U-MRD remission. At 12 months of the combination, 88% of the patients were in CR/CRi, with 61% achieving BM U-MRD remission. Older and high-risk patients showed similar response and MRD rates compared with the overall population.

During the study period, 11 (14%) patients discontinued study treatments, 5 during IBR monotherapy and 6 during the combination phase. Easy bruising, arthralgia, and diarrhea were the most common nonhematologic adverse events, each occurring in over 40% of patients. Grade 3/4 neutropenia occurred in 48% of patients. IBR was dose-reduced in 35 (44%) patients; the most common reason was atrial fibrillation, which occurred in 9 of the patients.

Researchers concluded that VEN-IBR combination therapy is an effective, safe, and chemotherapy-free oral regimen for patients with high-risk treatment-naïve CLL, with similar response in older adults and across all high-risk subgroups. Adverse event profiles were similar to what has been reported individually with IBR and VEN.

Jain N, et al. ASH 2018. Abstract 186.

Related Items
Prognostic Testing and Treatment Approaches in Patients with CLL: Interim Analysis of the informCLL Real-World Registry
Conference Correspondent published on December 4, 2018 in ASH 2018 - CLL
Acalabrutinib in Patients with Relapsed/Refractory and High-Risk, Treatment-Naïve CLL
Conference Correspondent published on December 4, 2018 in ASH 2018 - CLL
Cost-Effectiveness Comparison of Ibrutinib, Chemotherapy, and Chemoimmunotherapy in First-Line Treatment of CLL
Conference Correspondent published on December 4, 2018 in ASH 2018 - CLL
ECOG-ACRIN Cancer Research Group: Phase 3 Study of Ibrutinib-Based Therapy in Untreated Younger Patients with CLL
Conference Correspondent published on December 4, 2018 in ASH 2018 - CLL
Ibrutinib Treatment in Waldenström’s Macroglobulinemia: Follow-Up Efficacy and Safety from the iNNOVATE Study
Conference Correspondent published on December 2, 2018 in ASH 2018 - CLL
Last modified: December 2, 2018
  •  Association for Value-Based Cancer Care
  • Value-Based Cancer Care
  • Value-Based Care in Rheumatology
  • Oncology Practice Management
  • Rheumatology Practice Management
  • Urology Practice Management
  • Inside Patient Care: Pharmacy & Clinic
  • Lynx CME